Ying Du Sells 50,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

Key Points

• CEO Ying Du sold 50,000 shares of Zai Lab Limited, representing an 8.52% decrease in his ownership, for a total of nearly $1.74 million.
• Zai Lab's stock price has recently decreased, trading at $34.31, with a market cap of $3.81 billion and a negative PE ratio of -16.82.
• Recent institutional investments have significantly increased, including a 749.1% increase in FMR LLC's stake, indicating growing interest from major investors.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 50,000 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.74, for a total transaction of $1,737,000.00. Following the completion of the sale, the chief executive officer owned 536,962 shares of the company's stock, valued at $18,654,059.88. This trade represents a 8.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ying Du also recently made the following trade(s):

• On Monday, August 11th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.64, for a total transaction of $1,732,000.00.
• On Wednesday, July 2nd, Ying Du sold 7,072 shares of Zai Lab stock. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56.
• On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $855,160.97.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01.

Zai Lab Stock Down 1.0%

Zai Lab stock traded down $0.35 during trading on Tuesday, reaching $34.31. The stock had a trading volume of 394,193 shares, compared to its average volume of 995,749. Zai Lab Limited Unsponsored ADR has a 52-week low of $16.01 and a 52-week high of $44.34. The business has a 50 day moving average price of $36.70 and a 200 day moving average price of $33.36. The stock has a market cap of $3.81 billion, a PE ratio of -16.82 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The company had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. On average, equities analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ZLAB. FMR LLC raised its position in Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after purchasing an additional 4,830,646 shares during the last quarter. RTW Investments LP purchased a new stake in Zai Lab in the 4th quarter valued at $65,714,000. Mirae Asset Global Investments Co. Ltd. raised its position in Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares during the last quarter. RA Capital Management L.P. purchased a new stake in Zai Lab in the 4th quarter valued at $33,917,000. Finally, Principal Financial Group Inc. raised its position in Zai Lab by 63.6% in the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ZLAB shares. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Citigroup reiterated a "buy" rating and set a $69.00 price target (up from $66.00) on shares of Zai Lab in a research report on Monday. Finally, Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a research report on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Zai Lab has a consensus rating of "Moderate Buy" and an average price target of $57.22.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.